Grant: Proof of Principle Program - Phase II
University of Toronto
$189,920.00
Development and Commercialisation of Allosteric Modulators for the Treatment of Pain
EF 2014-15
Résumé
The body contains receptors which are activated by compounds called cannabinoids. These are called cannabinoid CB1
and CB2 receptors. Cannabinoids called endocannabinoids are produced in the tissues where they interact with cannabinoid
receptors to modulate physiological responses. Endocannabinoids are involved in learning and memory, appetite
stimulation, pain processing and mood. The levels of these compounds in the body increase in certain diseases, where they
act to relieve symptoms. Compounds which inhibit the enzymatic breakdown of the endocannabinoids are being tested in
clinical trials for the treatment of pain, depression and anxiety. Activators or agonists of the CB1 receptor are not ideal as
drugs because they produced unwanted psychoactive side-effects. We have discovered compounds which act in such a
way that they do not activate the CB1 receptor, but rather enhance the effects of the endocannabinoids. In this application
we will modify the chemical nature of this compound to make it a better drug and we will investigate the effectiveness of the
compound as a new therapeutic treatment for various types of pain.
Programme
Proof of Principle Program - Phase II
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
315080
Name
Ross Ruth A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Signal Pharma Ltd. (Scotland); Signal Pharma Ltd. (Scotland)
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Development and Commercialisation of Allosteric Modulators for the Treatment of Pain
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$189,920
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase II
Keyworddelim
Drug Discovery; Pain
Abstract
The body contains receptors which are activated by compounds called cannabinoids. These are called cannabinoid CB1
and CB2 receptors. Cannabinoids called endocannabinoids are produced in the tissues where they interact with cannabinoid
receptors to modulate physiological responses. Endocannabinoids are involved in learning and memory, appetite
stimulation, pain processing and mood. The levels of these compounds in the body increase in certain diseases, where they
act to relieve symptoms. Compounds which inhibit the enzymatic breakdown of the endocannabinoids are being tested in
clinical trials for the treatment of pain, depression and anxiety. Activators or agonists of the CB1 receptor are not ideal as
drugs because they produced unwanted psychoactive side-effects. We have discovered compounds which act in such a
way that they do not activate the CB1 receptor, but rather enhance the effects of the endocannabinoids. In this application
we will modify the chemical nature of this compound to make it a better drug and we will investigate the effectiveness of the
compound as a new therapeutic treatment for various types of pain.
Competitiondate
201409
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ross, Ruth A
Approvedterm
1 an 0 mois
Cihrcontribution2
Knowledge Translation Branch~ $189,920~ $0~